PRF Technologies Ltd.(PRFX)Earnings, Financials & Key Ratios
PRFX•NASDAQ
$1.51
Price updated Jun 27, 2026
AboutPainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.Show more
- Revenue$17K
- EBITDA-$4M+71.3%
- Net Income-$5M+66.8%
- EPS (Diluted)-7.47+99.1%
- Gross Margin-4864.71%
- EBITDA Margin-24782.35%
- Operating Margin-29335.29%
- Net Margin-28458.82%
- ROE-87.06%+73.0%
PRFX Price & Volume
PRF Technologies Ltd. (PRFX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Shareholder Equity Value
Investment Thesis • Updated 2025Q2
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"PRF Technologies remains a pre-revenue entity heavily reliant on external capital to fund its PRF-110 delivery platform development, as evidenced by a $58.8 million accumulated deficit. The company's reliance on equity-based financing to cover quarterly operating losses of $1.2 million creates significant dilution risk for existing shareholders. Investors should monitor the company's ability to secure non-dilutive funding, as the current cash balance of $3.5 million provides a limited runway for ongoing Phase 3 clinical trials."
Verdict Logic
the company's unsustainable cash-to-burn ratio and the $58.8 million accumulated deficit suggest imminent liquidity risks and further shareholder dilution.
PRFX Growth Metrics
PRF Technologies Ltd. (PRFX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-41.75%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM76.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM98.84%
Return on Capital
10 Years-305.14%
5 Years-118.86%
3 Years-164.44%
Last Year-85.69%
Peers Comparison
Key metrics vs top competitors for PRF Technologies Ltd. (PRFX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.51 | $128.26K | -0.20 | — | -28458.82% | -87.06% | — | |
| $25.24 | $992.82M | 157.75 | 3.63% | 1.27% | 1.31% | — | |
| $5.00 | $602.98M | -9.43 | -58.19% | -832.58% | -55.89% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $2.36 | $259.66K | -0.25 | — | -227.72% | -25.53% | — | |
| $4.76 | $1.78B | 11.07 | 8.53% | -11.27% | — | — |
Compare PRFX vs Peers
PRF Technologies Ltd. (PRFX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when PRFX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PRFX Frequently Asked Questions
PRF Technologies Ltd. (PRFX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is PRF Technologies Ltd.'s revenue?
PRF Technologies Ltd. (PRFX) reported $0.0M in revenue for fiscal year 2025.
Is PRFX profitable?
PRF Technologies Ltd. (PRFX) reported a net loss of $4.1M for fiscal year 2025.
Dividend & Returns
What is PRFX's return on equity?
PRF Technologies Ltd. (PRFX) has a return on equity (ROE) of -87.1%. Negative ROE indicates the company is unprofitable.
What is PRF Technologies Ltd.'s free cash flow?
PRF Technologies Ltd. (PRFX) had negative free cash flow of $6.0M in fiscal year 2025, likely due to heavy capital investments.